Anti-hEGFR isotype family
The Anti-hEGFR isotype family features the variable region of cetuximab. Cetuximab is a chimeric human/mouse IgG1 monoclonal antibody that targets EGFR, a cell surface receptor overexpressed in many types of cancer. Binding of cetuximab to EGFR blocks ligand/receptor binding, and induces receptor internalization and subsequent degradation.
Cetuximab has been approved by the FDA for the treatment of metastatic colorectal cancer and metastatic squamous cell carcinoma of the head and neck.
Antibodies of the anti-hEGFR isotype family have been generated by recombinant DNA technology. They have been produced in CHO cells and purified by different types of affinity chromatography: protein G for IgG1 and IgG4 and peptide M for IgA2.